MediWound to Present at Upcoming Investor Conferences in February
YAVNE,
| BTIG MedTech, |
|
| Date: | |
| Time: | |
| Format: | Fireside Chat |
| Registration Link: | Click here |
| Date: | |
| Time: | |
| Link: | Aegis Virtual Conference Calendar |
A replay of the fireside chat and presentation will be available on the Events page of the MediWound Investor Relations website at https://ir.mediwound.com/events-and-presentations.
About
NexoBrid®, our commercial orphan biological product for non-surgical eschar removal of deep-partial and full-thickness thermal burns, is a bromelain-based biological product containing a sterile mixture of proteolytic enzymes that selectively removes burn eschar within four hours without harming surrounding viable tissue. NexoBrid is currently marketed in the
EscharEx®, our next-generation bioactive topical therapeutic under development in the U.S. for debridement of chronic and hard to heal wounds. In two Phase 2 studies, EscharEx was well-tolerated and has demonstrated safety and efficacy in the debridement of various chronic and other hard-to-heal wounds, within a few daily applications.
MW005®, our topical biological drug for the treatment of non-melanoma skin cancers, is a clinical-stage product candidate under development.
Committed to innovation, we are dedicated to improving quality of care and patient lives. For more information, please visit www.mediwound.com.
| Contacts: |
|
| Chief Financial Officer | Managing Director, |
| MediWound Ltd. | 212-915-3820 |
| ir@mediwound.com | monique@lifesciadvisors.com |
Source: MediWound Ltd.